Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion
NEW YORK – Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion.
NEW YORK – Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion.